Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study-Reference-Cited by-同舟云学术

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study

Published:2017 Issue:3 Volume:2 Page:e000241
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Cremolini Chiara,Pietrantonio Filippo,Tomasello Gianluca,Dadduzio Vincenzo,Moretto Roberto,Morano Federica,Schirripa Marta,Antoniotti Carlotta,Fucà Giovanni,Bergamo Francesca,Rossini Daniele,Nichetti Federico,Ziampiri Stamatia,Ghidini Michele,Marmorino Federica,Prisciandaro Michele,Falcone Alfredo,De Braud Filippo,Loupakis Fotios,Lonardi Sara

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference14 articles.

1. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation;Tie;Int J Cancer,2011

2. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC);Corcoran;Ann Oncol,2016

3. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation;Hong;Cancer Discov,2016

4. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406);Kopetz;J Clin Oncol,2017

5. A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer;van Geel;Cancer Discov,2017

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies;International Journal of Molecular Sciences;2024-08-30

2. Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer;Cell Reports;2023-04

3. Inhibition of insulin‐like growth factor‐1 receptor enhances eribulin‐induced DNA damage in colorectal cancer;Cancer Science;2022-09-13

4. Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer;Therapeutic Advances in Gastroenterology;2022-01

5. Preclinical models as patients’ avatars for precision medicine in colorectal cancer: past and future challenges;Journal of Experimental & Clinical Cancer Research;2021-06-05